Oral BioLife, a regenerative technology company developing non-invasive therapies to restore bone and soft tissue, has appointed Greg Ambra as chief executive officer.

Ambra, who has nearly 30 years of global leadership experience in clinical development, operations, and commercialization, will guide the company through its next phase of growth across the animal health, dental, and orthopedic markets.

Founder and chairwoman Stella Vnook said: “Greg’s appointment comes at a pivotal moment for OBL, as we build on the exciting progress made with our lead asset, Ambrilux Dental Gel, which has demonstrated compelling results in preclinical studies and is advancing toward FDA approval and commercialization. His decades of leadership across pharma and biotech and proven track record in bringing transformative therapies to market make him uniquely suited to accelerate our mission of redefining treatment options for periodontal disease and beyond.”

Ambra added: “I am honored to join Oral BioLife at such a transformative moment in the company’s journey. I have great confidence in the strength of our pioneering technology, which holds the potential to meaningfully improve patients’ lives. Together with our exceptional team, I look forward to advancing real-world solutions that will make a lasting impact across healthcare.”

In addition, Oral BioLife has appointed Tim Glennon as chief commercialization officer and Mahesh Sambasivam as head of manufacturing. Glennon brings experience launching more than 15 medical devices and drugs, while Sambasivam has over 20 years in the medical device sector with a focus on FDA approvals and product launches.